The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10

B. P. Huta, A. M. Roberts, E. S. Waters, V. Y. Yu, Robert Patrick Doyle, M. R. Mehlenbacher, F. Bou-Abdallah

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Atovaquone is a front-line antimalarial drug that functions by competitively inhibiting binding of coenzyme Q10 to the cytochrome bc 1 complex. Atovaquone is administered orally, but has low solubility and is poorly absorbed with high variability in bioavailability. In vivo binding of human serum albumin has been cited as the major transporter of atovaquone in plasma. The research presented herein demonstrates that saposin B, a known binder/transporter of coenzyme Q10, also binds to atovaquone in a 1:1 ratio and with comparably high affinity at pH 5.5.

Original languageEnglish (US)
Pages (from-to)787-791
Number of pages5
JournalMedChemComm
Volume5
Issue number6
DOIs
StatePublished - 2014

Fingerprint

coenzyme Q10
Saposins
Atovaquone
Antimalarials
Cytochromes
Serum Albumin
Solubility
Biological Availability
Binders
Plasmas
Research

ASJC Scopus subject areas

  • Biochemistry
  • Pharmaceutical Science

Cite this

Huta, B. P., Roberts, A. M., Waters, E. S., Yu, V. Y., Doyle, R. P., Mehlenbacher, M. R., & Bou-Abdallah, F. (2014). The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10. MedChemComm, 5(6), 787-791. https://doi.org/10.1039/c3md00373f

The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10. / Huta, B. P.; Roberts, A. M.; Waters, E. S.; Yu, V. Y.; Doyle, Robert Patrick; Mehlenbacher, M. R.; Bou-Abdallah, F.

In: MedChemComm, Vol. 5, No. 6, 2014, p. 787-791.

Research output: Contribution to journalArticle

Huta, BP, Roberts, AM, Waters, ES, Yu, VY, Doyle, RP, Mehlenbacher, MR & Bou-Abdallah, F 2014, 'The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10', MedChemComm, vol. 5, no. 6, pp. 787-791. https://doi.org/10.1039/c3md00373f
Huta, B. P. ; Roberts, A. M. ; Waters, E. S. ; Yu, V. Y. ; Doyle, Robert Patrick ; Mehlenbacher, M. R. ; Bou-Abdallah, F. / The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10. In: MedChemComm. 2014 ; Vol. 5, No. 6. pp. 787-791.
@article{ca667d10d62f485d8a3475d4f24ddda5,
title = "The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10",
abstract = "Atovaquone is a front-line antimalarial drug that functions by competitively inhibiting binding of coenzyme Q10 to the cytochrome bc 1 complex. Atovaquone is administered orally, but has low solubility and is poorly absorbed with high variability in bioavailability. In vivo binding of human serum albumin has been cited as the major transporter of atovaquone in plasma. The research presented herein demonstrates that saposin B, a known binder/transporter of coenzyme Q10, also binds to atovaquone in a 1:1 ratio and with comparably high affinity at pH 5.5.",
author = "Huta, {B. P.} and Roberts, {A. M.} and Waters, {E. S.} and Yu, {V. Y.} and Doyle, {Robert Patrick} and Mehlenbacher, {M. R.} and F. Bou-Abdallah",
year = "2014",
doi = "10.1039/c3md00373f",
language = "English (US)",
volume = "5",
pages = "787--791",
journal = "MedChemComm",
issn = "2040-2503",
publisher = "Royal Society of Chemistry",
number = "6",

}

TY - JOUR

T1 - The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10

AU - Huta, B. P.

AU - Roberts, A. M.

AU - Waters, E. S.

AU - Yu, V. Y.

AU - Doyle, Robert Patrick

AU - Mehlenbacher, M. R.

AU - Bou-Abdallah, F.

PY - 2014

Y1 - 2014

N2 - Atovaquone is a front-line antimalarial drug that functions by competitively inhibiting binding of coenzyme Q10 to the cytochrome bc 1 complex. Atovaquone is administered orally, but has low solubility and is poorly absorbed with high variability in bioavailability. In vivo binding of human serum albumin has been cited as the major transporter of atovaquone in plasma. The research presented herein demonstrates that saposin B, a known binder/transporter of coenzyme Q10, also binds to atovaquone in a 1:1 ratio and with comparably high affinity at pH 5.5.

AB - Atovaquone is a front-line antimalarial drug that functions by competitively inhibiting binding of coenzyme Q10 to the cytochrome bc 1 complex. Atovaquone is administered orally, but has low solubility and is poorly absorbed with high variability in bioavailability. In vivo binding of human serum albumin has been cited as the major transporter of atovaquone in plasma. The research presented herein demonstrates that saposin B, a known binder/transporter of coenzyme Q10, also binds to atovaquone in a 1:1 ratio and with comparably high affinity at pH 5.5.

UR - http://www.scopus.com/inward/record.url?scp=84901669634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901669634&partnerID=8YFLogxK

U2 - 10.1039/c3md00373f

DO - 10.1039/c3md00373f

M3 - Article

AN - SCOPUS:84901669634

VL - 5

SP - 787

EP - 791

JO - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 6

ER -